Influence of anabolic steroid on anxiety levels in sedentary male rats

Stress

Volumn 10, Issue 4, 2007, Pages 326-331

  Rocha, V M ^a   Calil, C M ^a   Ferreira, R ^a   Moura, M J C S ^b   Marcondes, F K ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

Author keywords

Anabolic steroid; Anxiety; GABAA receptor; Nandrolone; Rats

Indexed keywords

ANABOLIC AGENT; DIAZEPAM; NANDROLONE DECANOATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL HUSBANDRY; ANIMAL TISSUE; ANXIETY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HORMONE ACTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SITTING; TASK PERFORMANCE;

ANABOLIC AGENTS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; DIAZEPAM; MALE; MAZE LEARNING; MOTOR ACTIVITY; NANDROLONE; PROPYLENE GLYCOL; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; STEROIDS;

EID: 36248959771     PISSN: 10253890     EISSN: 16078888     Source Type: Journal    
DOI: 10.1080/10253890701281344     Document Type: Article

References (60)

1. Ahmadiani A, Mandgary A, Sayyah M. 2003. Anticonvulsant effect of flutamide on seizures induced by pentylenetetrazole: Involvement of benzodiazepine receptors. Epilepsia 44:629-635.
2. Aikey JL, Nyby JG, Anmuth DM, James PJ. 2002. Testosterone rapidly reduces anxiety in male house mice (Mus musculus). Horm Behav 42:448-460.
3. Anseloni VZ, Brandǎo ML. 1997. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus maze. Behav Pharmacol 8:533-540.
4. Bahrke MS, Yesalis CE, III, Wright J. 1990. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males. A review. Sports Med 10:303-337.
5. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. 1991. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 17:29-33.
6. Bates KA, Harvey AR, Carruthers M, Martins RN. 2005. Androgens, andropause and neurodegeneration: Exploring the link between steroidogenesis, androgens and Alzheimer's disease. Cell Mol Life Sci 62:281-292.
7. Berns JS, Rudnick MR, Cohen RM. 1992. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 37:264-267.
8. Bing O, Heilig M, Kakoulidis P, Sundblad C, Wiklund L, Eriksson E. 1998. High doses of testosterone increase anticonflict behaviour in rat. Eur Neuropsychopharmacol 8:321-323.
9. Bitran D, Dowd JA. 1996. Ovarian steroids modify the behavioral and neurochemical responses of the central benzodiazepine receptor. Psychopharmacology (Berl) 125:65-73.
10. Bitran D, Kellogg CK, Hilvers RJ. 1993. Treatment with an anabolic-androgenic steroid affects anxiety-related behavior and alters the sensitivity of cortical GABAA receptors in the rat. Horm Behav 4:568-583.
11. Boskovitz EP, Cruz ETN, Neto FC, Moraes MS, Netto JVP, Ávila LA. 1995. Uso de drogas entre estudantes universitários em São José do Rio Preto, São Paulo. Rev Bras Psiquiatr 22:87-93.
12. Breuer ME, Mcginnis MY, Lumia AR, Possidente BP. 2001. Aggression in male rats receiving anabolic androgenic steroids: Effects of social and environmental provocation. Horm Behav 40:409-418.
13. Brower KJ, Eliopulus GA, Blow FC, Catlin DH, Beresford TP. 1990. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. Am J Psychiatry 147:510-512.
14. Creutzberg EC, Schols AMWJ. 1999. Anabolic steroids. Curr Opin Clin Nutr Metab Care 2:243-253.
15. Crist DM, Stackpole PJ, Peake GT. 1983. Effects of androgenic anabolic steroids on neuromuscular power and body composition. J Appl Physiol 54:366-370.
16. Cruz APM, Frei F, Graeff FG. 1994. Ethopharmarcological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49:171-176.
17. Cunha TS, Cunha NS, Moura MJCS, Marcondes FK. 2004. Anabolic androgenic steroids and the relation to the sportive practice. Braz J Pharmac Sci 40:165-179.
18. Cunha TS, Tanno AP, Moura MJCS, Marcondes FK. 2005a. Influence of high-intensity exercise training and anabolic androgenic steroid treatment on rat tissue glycogen content. Life Sci 77:1030-1043.
19. Cunha TS, Moura MJCS, Bernardes CF, Tanno AP, Marcondes FK. 2005b. Vascular sensitivity to phenylefrine in rats submitted to anaerobic training and nandrolone treatment. Hypertension 46:1010-1015.
20. Currier JS. 2000. How to manage metabolic complications of HIV therapy: What to do while we wait for answers. AIDS Read 10:162-169.
21. Fernández-Guasti A, Martínez-Mota L. 2005. Anxiolytic-like actions of testosterone in the burying behavior test: Role of androgen and GABA-benzodiazepine receptors. Psychoneuroendocrinology 30:762-770.
22. Galduróz JC, Noto AR, Carlini EA. 1997. Levantamento sobre o uso de drogas entre estudantes de 1° e 2° graus em 10 capitais brasileiras. Brazil: Centro Brasileiro sobre Drogas Psicotrópicas. Escola Paulista de Medicina.
23. Gordon CM, Glowacki J, Leboff MS. 1999. DHEA and the skeleton (through the ages). Endocrine 11:1-11.
24. Graeff FG, Zangrossi H. 2002. Animal models of anxiety disorders. Biol Psychiatry Disord :2-15.
25. Green S, Hodges H. 1991. Animal models of anxiety. In: Willner P, editor. Behavioural models in psychopharmacology. Cambridge: Cambridge University Press. p 21-49.
26. Gruber AJ, Pope HG, Jr. 2000. Psychiatric and medical effects of anabolic androgenic steroid use in women. Psychother Psychosom 69:19-26.
27. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF. 2003. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23: 6690-6694.
28. Hobbs CJ, Jones RE, Plymate SR. 1996. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. J Clin Endocrinol Metab 81:1582-1585.
29. Johansson-Steensland P, Nyberg F, Chahl L. 2002. The anabolic androgenic steroid, nandrolone decanoate, increases the density of Fos-like immunoreactive neurons in limbic regions of guineapig brain. Eur J Neurosci 15:539-544.
30. Johnson WO. 1985. Steroids: A problem of huge dimensions. Sports Illustrated 5:38-54.
31. Kuhn CM. 2002. Anabolic steroids. Recent Prog Horm Res 57: 411-434.
32. Lise MLZ, Gama Silva TS, Ferigolo M, Barros HMT. 1999. O abuso de esteróides anabólico-androgênicos em atletismo. Rev Assoc Med Bras 45:364-370.
33. Lucas ACS, Parente RCP, Picanço NS, Conceição DA, Costa KRC, Magalhães IRS, Siqueira JCA. 2006. Uso de psicotrópicos entre universitários da área da saúde da Universidade Federal do Amazonas, Brasil. Cad Saúde Pública 22:663-671.
34. Magalhães MP, Barros RS, Silva MTA. 1991. Uso de drogas entre universitários: A experiência com a maconha como fator delimitante. Rev ABP-APAL 13:97-104.
35. Marcondes FK, Miguel KJ, Melo LL, Spadari-Bratfisch RC. 2001. Estrous cycle influences the response of female rats in the elevated plus maze. Physiol Behav 74:435-440.
36. McCarthy MM. 1995. Functional significance of steroid modulation of GABAergic neurotransmission: Analysis at the behavioral, cellular, and molecular levels. Horm Behav 29:131-140.
37. McEwen BS. 1991. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol 12:141-147.
38. Melcangi RC, Celotti F, Ballabio M, Poletti A, Martini L. 1990. Testosterone metabolism in peripheral nerves: Presence of the 5 alpha-reductase-3 alpha-hydroxysteroid dehydrogenase enzymatic system in the sciatic nerve of adult and aged rats. J Steroid Biochem 35:145-148.
39. Minkin DM, Meyer ME, van Haaren F. 1993. Behavioral effects of long-term administration of an anabolic steroid in intact and castrated male Wistar rats. Pharmacol Biochem Behav 44:959-963.
40. Oliveira M, Bessa JM, Mesquita A, Tavares H, Carvalho A, Silva R, Pego JM, Cerqueira JJ, Palha JA, Almeida OF, Sousa N. 2006. Induction of a hyperanxious state by antenatal dexamethasone: A case for less detrimental natural corticosteroids. Biol Psychiatry 59:844-852.
41. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. 2006a. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlated to the severity of abuse. Eur Psychiatry 21:551-562.
42. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS, Toli PN. 2006b. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur Psychiatry 21:563-569.
43. Pellow S, Chopin P, File SE, Briley M. 1985. Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rats. J Neurosci Methods 14:49-167.
44. Pereira LO, Cunha IC, Neto JM, Paschoalini MA, Faria MS. 2005. The gradient of luminosity between open/enclosed arms, and not the absolute level of lux, predicts the behaviour of rats in the plus maze. Behav Brain Res 159:55-61.
45. Picazo O, Fernandez-Guasti A. 1995. Anti-anxiety effects of progesterone and some of its reduced metabolites: An evaluation using the burying behavior test. Brain Res 680:135-141.
46. Pizzol TDAS, Branco MM, Carvalho RM, Pasqualotti A, Maciel EN, Migott AM. 2006. Non-medical use of psychoactive medicines among elementary and high school students in Southern Brazil. Cad Saúde Pública 22:109-115.
47. Poletti A, Negri-Cesi P, Melcangi RC, Colciago A, Martini L, Celotti F. 1997. Expression of androgen-activating enzymes in cultured cells of developing rat brain. J Neurochem 68:1298-1303.
48. Pope HG, Jr., Katz DL. 1988. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 145:487-490.
49. Rabkin JG, Wagner GJ, Rabkin R. 2000. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 57:141-147.
50. Rojas-Ortiz YA, Rundle-González V, Rivera-Ramos I, Jorge JC. 2006. Modulation of elevated plus maze behavior offer chronic exposure to the anabolic steroid 17-alpha-methyltestosterone in adult mice. Horm Behav 49:123-128.
51. Roselli CE. 1998. The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area. Brain Res 792:271-276.
52. Rupprecht R, Holsboer F. 1999. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22:410-416.
53. Salvador A, Moya-Albiol L, Martinez-Sanchis S, Simon VM. 1999. Lack of effects of anabolic-androgenic steroids on locomotor activity in intact male mice. Percept Mot Skills 88:319-328.
54. Shekhar A. 1993. GABA receptors in the region of the dorsomedial hypothalamus of rats regulate anxiety in the elevated plus-maze test. I. Bheavioral measures. Brain Res 627:9-16.
55. Shekhar A, Katner JS. 1995. Dorsomedial hypothalamics GABA regulates anxiety in the social interaction test. Pharmacol Biochem Behav 50:253-258.
56. Tanno AP, Rosa KT, Cunha TS, Giordano FCL, Calil CM, Novaes PD, Irigoyen MC, Marcondes FK. 2006. High dose of anabolic steroid impairs cardiac function in rats. J Venom Anim Toxins incl Trop Dis 12:672.
57. Titlestad SD, Lambert MI, Schwellnus MP. 1994. A survey to determine types and dosages of anabolic androgenic steroids used by competitive bodybuilders in South Africa. J Sports Med 1:24-28.
58. Van Wayjen RGA. 1972. Clinical-pharmacological basis of anabolic treatment. Tijdschr Geneaskd 28:554-571.
59. A receptors. Neuropharmacology 43:619-633.
60. Yesalis CE, Courson SP, Wright JE. 1993. History of anabolic steroid in sport and exercise Anabolic steroids in sport and exercise. Champaign: Human Kinetics. p 51-71.